Tags

Type your tag names separated by a space and hit enter

Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
J Diet Suppl 2018; 15(5):606-612JD

Abstract

Hand-foot syndrome (HFS) is common and frequently occurs in the first cycle of treatment in approximately 40% to 50% of patients who receive capecitabine. Turmeric (Curcuma longa) is a plant used in Ayurvedic medicine with clinical activity in various inflammatory conditions. Our objective was to evaluate whether turmeric was active for the prevention of capecitabine-induced HFS. We included patients older than 18 years of age without previous exposure to capecitabine who were scheduled to receive this medication. Before starting treatment, after three weeks and at the end of six weeks, we evaluated dermatologic toxicity, conducted quality-of-life questionnaires (EORTC-QLQC30 and DLQI) and collected serum inflammatory biomarkers (inerleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), C-reactive protein (CRP), and albumin). We administered turmeric at a dose of 4 g/day (2 pills 12 hours apart) starting at the beginning of capecitabine treatment and lasting six weeks. We included 40 patients whose mean age was 62 years. Most were female (80%), 52% had breast cancer, and 47.5% had GI tumors. After the first cycle of capecitabine treatment, we observed that 11 of 40 patients developed HFS (27.5%; 95% CI [15, 42]), whereas four patients developed HFS equal or superior to grade 2 (10%; 95% CI [3.3, 23]). We did not find any correlations between the inflammatory markers tested and HFS. We show that turmeric combined with capecitabine seems to produce a lower rate of HFS, especially grade 2 or higher. These findings need to be reproduced in larger controlled studies.

Authors+Show Affiliations

a Abc Foundation Medical School, Oncology , Faculdade de Medicina do ABC , Santo Andre , Brazil.b Abc Foundation Medical School , Faculdade de Medicina do ABC , Santo Andre , Brazil.b Abc Foundation Medical School , Faculdade de Medicina do ABC , Santo Andre , Brazil.b Abc Foundation Medical School , Faculdade de Medicina do ABC , Santo Andre , Brazil.b Abc Foundation Medical School , Faculdade de Medicina do ABC , Santo Andre , Brazil.b Abc Foundation Medical School , Faculdade de Medicina do ABC , Santo Andre , Brazil.c Abc Foundation Medical School, Oncology , FMABC , Santo Andre , Brazil.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29095653

Citation

Scontre, Vanessa Armenio, et al. "Curcuma Longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: a Pilot Study." Journal of Dietary Supplements, vol. 15, no. 5, 2018, pp. 606-612.
Scontre VA, Martins JC, de Melo Sette CV, et al. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study. J Diet Suppl. 2018;15(5):606-612.
Scontre, V. A., Martins, J. C., de Melo Sette, C. V., Mutti, H., Cubero, D., Fonseca, F., & Del Giglio, A. (2018). Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study. Journal of Dietary Supplements, 15(5), pp. 606-612. doi:10.1080/19390211.2017.1366387.
Scontre VA, et al. Curcuma Longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: a Pilot Study. J Diet Suppl. 2018 Sep 3;15(5):606-612. PubMed PMID: 29095653.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study. AU - Scontre,Vanessa Armenio, AU - Martins,Janine Capobiango, AU - de Melo Sette,Claudia Vaz, AU - Mutti,Haila, AU - Cubero,Daniel, AU - Fonseca,Fernando, AU - Del Giglio,Auro, Y1 - 2017/11/02/ PY - 2017/11/3/pubmed PY - 2018/11/6/medline PY - 2017/11/3/entrez KW - Curcuma KW - capecitabine KW - hand-foot syndrome SP - 606 EP - 612 JF - Journal of dietary supplements JO - J Diet Suppl VL - 15 IS - 5 N2 - Hand-foot syndrome (HFS) is common and frequently occurs in the first cycle of treatment in approximately 40% to 50% of patients who receive capecitabine. Turmeric (Curcuma longa) is a plant used in Ayurvedic medicine with clinical activity in various inflammatory conditions. Our objective was to evaluate whether turmeric was active for the prevention of capecitabine-induced HFS. We included patients older than 18 years of age without previous exposure to capecitabine who were scheduled to receive this medication. Before starting treatment, after three weeks and at the end of six weeks, we evaluated dermatologic toxicity, conducted quality-of-life questionnaires (EORTC-QLQC30 and DLQI) and collected serum inflammatory biomarkers (inerleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), C-reactive protein (CRP), and albumin). We administered turmeric at a dose of 4 g/day (2 pills 12 hours apart) starting at the beginning of capecitabine treatment and lasting six weeks. We included 40 patients whose mean age was 62 years. Most were female (80%), 52% had breast cancer, and 47.5% had GI tumors. After the first cycle of capecitabine treatment, we observed that 11 of 40 patients developed HFS (27.5%; 95% CI [15, 42]), whereas four patients developed HFS equal or superior to grade 2 (10%; 95% CI [3.3, 23]). We did not find any correlations between the inflammatory markers tested and HFS. We show that turmeric combined with capecitabine seems to produce a lower rate of HFS, especially grade 2 or higher. These findings need to be reproduced in larger controlled studies. SN - 1939-022X UR - https://www.unboundmedicine.com/medline/citation/29095653/Curcuma_longa__Turmeric__for_Prevention_of_Capecitabine_Induced_Hand_Foot_Syndrome:_A_Pilot_Study_ L2 - http://www.tandfonline.com/doi/full/10.1080/19390211.2017.1366387 DB - PRIME DP - Unbound Medicine ER -